Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Tumor differentiation enhances morphologic and microvascular heterogeneity fostering hypoxia that retards intratumoral drug delivery, distribution, and compromise therapeutic efficacy. In this study, the influence of tumor biologic heterogeneity on the interaction between cytotoxic chemotherapy and selenium was examined using a panel of human tumor xenografts representing cancers of the head and neck and lung along with tissue microarray analysis of human surgical samples. Tumor differentiation status, microvessel density, interstitial fluid pressure, vascular phenotype, and drug delivery were correlated with the degree of enhancement of chemotherapeutic efficacy by selenium. Marked potentiation of antitumor activity was observed in H69 tumors that exhibited a well-vascularized, poorly differentiated phenotype. In comparison, modulation of chemotherapeutic efficacy by antiangiogenic selenium was generally lower or absent in well-differentiated tumors with multiple avascular hypoxic, differentiated regions. Tumor histomorphologic heterogeneity was found prevalent in the clinical samples studied and represents a primary and critical physiological barrier to chemotherapy.

[1]  W. Marsden.  I and J , 2012 .

[2]  Y. Rustum,et al.  Double Immunohistochemical Staining Method for HIF-1α and its Regulators PHD2 and PHD3 in Formalin-fixed Paraffin-embedded Tissues , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  Y. Rustum,et al.  Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α , 2010, Cancer Chemotherapy and Pharmacology.

[4]  M. Seshadri,et al.  Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. , 2009, Clinical colorectal cancer.

[5]  M. Lerman,et al.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? , 2009, Biochimica et biophysica acta.

[6]  L. Ellis,et al.  Cancer: The nuances of therapy , 2009, Nature.

[7]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[8]  T. Crook,et al.  Why does cytotoxic chemotherapy cure only some cancers? , 2009, Nature Clinical Practice Oncology.

[9]  G. Combs,et al.  Selenium and anticarcinogenesis: underlying mechanisms , 2008, Current opinion in clinical nutrition and metabolic care.

[10]  Y. Rustum,et al.  Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. , 2008, Neoplasia.

[11]  M. Seshadri,et al.  Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer Drugs , 2008, Clinical Cancer Research.

[12]  M. Fakih,et al.  A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[13]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[14]  H. Verheul,et al.  Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.

[15]  A. Oza,et al.  A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. , 2007, International journal of radiation oncology, biology, physics.

[16]  M. Seshadri,et al.  Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. , 2006, Neoplasia.

[17]  M. Yin,et al.  Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1α expression, resulting in reduced angiogenesis , 2006, Oncogene.

[18]  P. Vaupel,et al.  Carbonic Anhydrase IX Expression and Tumor Oxygenation Status Do Not Correlate at the Microregional Level in Locally Advanced Cancers of the Uterine Cervix , 2005, Clinical Cancer Research.

[19]  A. Hargens,et al.  A simple method for measuring interstitial fluid pressure in cancer tissues. , 2005, Microvascular research.

[20]  Y. Rustum,et al.  Lack of Microvessels in Well-Differentiated Regions of Human Head and Neck Squamous Cell Carcinoma A253 Associated with Functional Magnetic Resonance Imaging Detectable Hypoxia, Limited Drug Delivery, and Resistance to Irinotecan Therapy , 2004, Clinical Cancer Research.

[21]  A. Schally,et al.  Suppression of growth of H‐69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling , 2004, International journal of cancer.

[22]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[23]  Y. Rustum,et al.  Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts , 2004, Clinical Cancer Research.

[24]  Howard L McLeod,et al.  Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts , 2004, Clinical Cancer Research.

[25]  P. Whanger.  Selenium and its relationship to cancer: an update† , 2004, British Journal of Nutrition.

[26]  D. Birle,et al.  Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Kevin Barraclough,et al.  I and i , 2001, BMJ : British Medical Journal.

[28]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[29]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[30]  D M Shames,et al.  A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution , 1997, Magnetic resonance in medicine.

[31]  D. Longo,et al.  Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. , 1993, Cancer research.

[32]  E. Brambilla,et al.  Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.